11 research outputs found

    Effect of milrinone on short-term outcome of patients with myocardial dysfunction undergoing coronary artery bypass graft: A randomized controlled trial

    Get PDF
    Background: Myocardial dysfunction needing inotropic support is a typical complication after on-pump cardiac surgery. In this study, we evaluate the effect of milrinone on patients with ventricular dysfunction undergoing coronary artery bypass graft (CABG). Methods: Seventy patients with impaired left ventricular function [left ventricular ejection fraction (LVEF) < 35%] undergoing on-pump CABG were enrolled. Patients were randomized to receive either an intraoperative bolus of milrinone (50 &#956;g/kg) or saline as placebo followed by a 24-hour infusion of each agent (0.5 &#956;g/kg/min). Hemodynamic parameters and transthoracic echocardiographic measurement of systolic and diastolic functions were the variables evaluated. Results: Serum levels of creatine phosphokinase (CPK), the MB isoenzyme of creatine kinase (CK-MB), occurrence of myocardial ischemia or infarction, and mean duration of using inotropic agents were significantly lower in the milrinone group (p < 0.05). There were no significant differences between the two groups regarding the development of ventricular arrhythmia, duration of cardiopulmonary bypass, intra-aortic balloon pump and inotropic support requirement, duration of mechanical ventilation, duration of intensive care unit stay and mortality rate. Although mean pre-operative LVEF was significantly lower in the milrinone group, there was no significant difference between post-operative LVEFs. Conclusions: We suggest that perioperative administration of milrinone in patients undergoing on-pump CABG, especially those with low LVEF, is beneficial. (Cardiol J 2010; 17, 1: 73-78

    Wp艂yw stosowania milrinonu na wczesne wyniki leczenia pacjent贸w z dysfunkcj膮 mi臋艣nia sercowego poddawanych pomostowaniu aortalno-wie艅cowemu: badanie kontrolowane z randomizacj膮

    Get PDF
    Wst臋p: Dysfunkcja mi臋艣nia sercowego wymagaj膮ca stosowania leczenia inotropowego jest cz臋stym powik艂aniem zabieg贸w kardiochirurgicznych z wykorzystaniem kr膮偶enia pozaustrojowego. W niniejszym badaniu podj臋to pr贸b臋 oceny wp艂ywu stosowania milrinonu u pacjent贸w z nieprawid艂ow膮 czynno艣ci膮 mi臋艣nia sercowego, poddawanych pomostowaniu aortalno-wie艅cowemu. Metody: Do badania w艂膮czono 70 pacjent贸w z upo艣ledzon膮 funkcj膮 lewej komory (frakcja wyrzutowa lewej komory - LVEF < 35%), u kt贸rych wykonano pomostowanie aortalno-wie艅cowe. Zostali oni losowo podzieleni na dwie grupy. Osoby z jednej z nich otrzymywa艂y w trakcie operacji milrinon w bolusie (50 &#956;g/kg mc.), natomiast chorzy z drugiej grupy roztw贸r soli fizjologicznej jako placebo. Nast臋pnie w ka偶dej grupie zastosowano 24-godzinny wlew wcze艣niej podanej substancji w przep艂ywie 0,5 &#956;g/kg mc./min. Analizie poddano dane hemodynamiczne oraz pomiary skurczowej i rozkurczowej funkcji serca uzyskane podczas echokardiografii przezklatkowej. Wyniki: Osoczowe st臋偶enie kinazy fosfokreatynowej (CPK), izoenzymu MB kinazy kreatynowej (CK-MB), cz臋sto艣膰 wyst臋powania niedokrwienia lub zawa艂u serca oraz 艣redni czas leczenia inotropowego by艂y znacz膮co ni偶sze w grupie pacjent贸w otrzymuj膮cych milrinon (p < 0,05). Nie stwierdzono istotnych r贸偶nic mi臋dzy grupami w wyst臋powaniu arytmii komorowych, d艂ugo艣ci trwania kr膮偶enia pozaustrojowego i wentylacji mechanicznej, konieczno艣ci stosowania kontrapulsacji wewn膮trzaortalnej i leczenia inotropowego, d艂ugo艣ci pobytu na oddziale intensywnej opieki medycznej oraz 艣miertelno艣ci. Mimo 偶e 艣rednia LVEF by艂a istotnie ni偶sza u pacjent贸w otrzymuj膮cych milrinon, nie stwierdzono istotnych r贸偶nic w 艣redniej LVEF w pooperacyjnej obserwacji badanych grup. Wnioski: Oko艂ooperacyjne stosowanie milrinonu jest korzystne u pacjent贸w poddawanych pomostowaniu aortalno-wie艅cowemu z wykorzystaniem kr膮偶enia pozaustrojowego, zw艂aszcza u chorych z obni偶on膮 LVEF. (Folia Cardiologica Excerpta 2010; 5, 5: 266-272

    Robot-Assisted Diagnostic Laparoscopy: A Safe and Feasible Adjunct to the Management of Massive Spontaneous Pneumoperitoneum

    No full text
    Pneumoperitoneum is the abnormal presence of free air in the peritoneal cavity. Oftentimes, it is a surgical emergency requiring exploratory laparotomy as most cases of pneumoperitoneum are due to perforated hollow viscus. However, not all pneumoperitoneum cases are surgical; nonsurgical pneumoperitoneum can arise from thoracic, abdominal, gynecologic, and other causes. We present a case of a 35-year-old male who developed a non-surgical pneumoperitoneum in the setting of drug overdose. The patient underwent robot-assisted diagnostic laparoscopy without findings of perforation or other pathology. Resolution of pneumoperitoneum was evidenced on follow-up computed tomography scan. This case emphasizes the importance of diagnostic laparoscopy in the setting of a confusing clinical picture and the feasibility of utilizing the robotic approach in hemodynamically stable patients

    Artyku艂 oryginalny Zwi膮zek pomi臋dzy Chlamydia pneumoniae w blaszkach mia偶d偶ycowych a czynnikami ryzyka rozwoju choroby wie艅cowej u chorych poddawanych rewaskularyzacji chirurgicznej

    No full text
    Background and aim: This study was conducted to investigate the prevalence of Chlamydia pneumoniae pathogen inside the atherosclerotic plaque of patients undergoing CABG by using PCR assay and to determine whether there is any association between the presence of bacteria in atherosclerotic lesions and classical coronary risk factors. Methods: In a cross-sectional study, 102 patients (20 to 79 years old; 73.5% male) undergoing CABG were evaluated in terms of major coronary risk factors and the presence of Chlamydia pneumoniae. Results: Chlamydia pneumoniae was found in 23.4% of coronary plaque specimens. Of these, two patients had no risk factor and the rest of the patients had 1 to 3 risk factors. Patients with positive PCR were more likely to have hypercholesterolaemia (p = 0.009) and low HDL levels (p = 0.000) in comparison with the PCR-negative group. There were no statistical differences for other risk factors. Conclusion: Our results imply the synergic contribution of Chlamydia pneumoniae DNA and known dyslipidaemia to the development of atherosclerotic lesions in patients undergoing CABG.Wst臋p: Od dawna sugerowano istnienie zwi膮zku pomi臋dzy rozwojem choroby wie艅cowej a infekcj膮 Chlamydia pneumoniae. Cel: Ocena cz臋sto艣ci wyst臋powania patogenu Chlamydia pneumoniae w blaszkach mia偶d偶ycowych uzyskanych z naczy艅 wie艅cowych chorych poddawanych operacji pomostowania aortalno-wie艅cowego (CABG). Metody: U 102 chorych (20&#8211;79 lat, 73,5% m臋偶czyzn), u kt贸rych wykonano CABG, oceniono czynniki ryzyka choroby wie艅cowej oraz zbadano blaszki mia偶d偶ycowe z pobranych fragment贸w t臋tnic wie艅cowych na obecno艣膰 Chlamydia pneumoniae (metoda PCR). Wyniki: Patogen Chlamydia pneumoniae zosta艂 wykryty w 23,4% badanych blaszek mia偶d偶ycowych. Spo艣r贸d chorych, od kt贸rych pochodzi艂y blaszki, u dw贸ch nie stwierdzono obecno艣ci czynnik贸w ryzyka chor贸b sercowo-naczyniowych, a u pozosta艂ych wyst臋powa艂o 1&#8211;3 takich czynnik贸w. Chorzy, u kt贸rych stwierdzono w blaszkach mia偶d偶ycowych Chlamydia pneumoniae, mieli znacz膮co cz臋艣ciej hipercholesterolemi臋 (p = 0,009) i niskie st臋偶enie cholesterolu HDL (p = 0,000) ni偶 chorzy bez tego patogenu. Wnioski: Wyniki naszego badania sugeruj膮 synergistyczny wp艂yw Chlamydia pneumoniae i dyslipidemii na rozw贸j blaszki mia偶d偶ycowej u chorych poddawanych CABG

    The association between Chlamydia pneumoniae DNA in atherosclerotic plaque and major risk factors in patients undergoing coronary artery bypass grafting

    No full text
    Background and aim: This study was conducted to investigate the prevalence of Chlamydia pneumoniae pathogen inside the atherosclerotic plaque of patients undergoing CABG by using PCR assay and to determine whether there is any association between the presence of bacteria in atherosclerotic lesions and classical coronary risk factors. Methods: In a cross-sectional study, 102 patients (20 to 79 years old; 73.5% male) undergoing CABG were evaluated in terms of major coronary risk factors and the presence of Chlamydia pneumoniae. Results: Chlamydia pneumoniae was found in 23.4% of coronary plaque specimens. Of these, two patients had no risk factor and the rest of the patients had I to 3 risk factors. Patients with positive PCR were more likely to have hypercholesterolaemia (p = 0.009) and low HDL levels (p = 0.000) in comparison with the PCR-negative group. There were no statistical differences for other risk factors. Conclusion: Our results imply the synergic contribution of Chlamydia pneumoniae DNA and known dyslipidaemia to the development of atherosclerotic lesions in patients undergoing CABG
    corecore